Q2 2024 Earnings Forecast for Celldex Therapeutics, Inc. (NASDAQ:CLDX) Issued By Lifesci Capital

Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) – Inventory analysts at Lifesci Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a analysis notice issued to buyers on Friday, June seventh. Lifesci Capital analyst S. Slutsky forecasts that the biopharmaceutical firm will put up earnings per share of ($0.62) for the quarter. The consensus estimate for Celldex Therapeutics’ present full-year earnings is ($2.32) per share.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) final issued its quarterly earnings outcomes on Monday, Could sixth. The biopharmaceutical firm reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.11. The corporate had income of $0.16 million for the quarter, in comparison with analysts’ expectations of $1.30 million. Celldex Therapeutics had a unfavorable return on fairness of 29.55% and a unfavorable web margin of two,385.57%.

CLDX has been the topic of a number of different analysis stories. Cantor Fitzgerald reaffirmed an “obese” score and issued a $67.00 goal worth on shares of Celldex Therapeutics in a analysis report on Friday, March twenty second. Guggenheim raised their goal worth on Celldex Therapeutics from $72.00 to $90.00 and gave the inventory a “purchase” score in a analysis report on Tuesday, February twenty seventh. Lastly, HC Wainwright reaffirmed a “purchase” score and issued a $80.00 goal worth on shares of Celldex Therapeutics in a analysis report on Monday, June third. One analysis analyst has rated the inventory with a maintain score and 4 have given a purchase score to the corporate’s inventory. Based mostly on knowledge from MarketBeat.com, the inventory presently has a consensus score of “Reasonable Purchase” and a consensus goal worth of $66.00.

Learn Our Newest Inventory Report on Celldex Therapeutics

Celldex Therapeutics Inventory Up 0.5 %

Shares of Celldex Therapeutics inventory opened at $35.28 on Monday. The inventory has a market cap of $2.33 billion, a PE ratio of -12.38 and a beta of 1.47. The enterprise has a fifty day easy shifting common of $38.26 and a 200-day easy shifting common of $38.76. Celldex Therapeutics has a 12 month low of $22.11 and a 12 month excessive of $53.18.

Insider Exercise at Celldex Therapeutics

In associated information, VP Richard M. Wright bought 46,844 shares of Celldex Therapeutics inventory in a transaction on Monday, June third. The inventory was bought at a mean worth of $33.72, for a complete transaction of $1,579,579.68. Following the completion of the sale, the vice chairman now owns 20,833 shares of the corporate’s inventory, valued at $702,488.76. The transaction was disclosed in a authorized submitting with the SEC, which is offered via the SEC web site. In different Celldex Therapeutics information, CFO Samuel Bates Martin bought 35,000 shares of the enterprise’s inventory in a transaction dated Thursday, Could thirtieth. The inventory was bought at a mean worth of $34.05, for a complete worth of $1,191,750.00. Following the completion of the sale, the chief monetary officer now owns 25,128 shares of the corporate’s inventory, valued at $855,608.40. The sale was disclosed in a authorized submitting with the Securities & Trade Fee, which is offered via this hyperlink. Additionally, VP Richard M. Wright bought 46,844 shares of the enterprise’s inventory in a transaction dated Monday, June third. The inventory was bought at a mean worth of $33.72, for a complete worth of $1,579,579.68. Following the completion of the sale, the vice chairman now straight owns 20,833 shares of the corporate’s inventory, valued at roughly $702,488.76. The disclosure for this sale may be discovered right here. Over the past 90 days, insiders bought 159,160 shares of firm inventory valued at $5,388,889. Insiders personal 3.80% of the corporate’s inventory.

Institutional Buying and selling of Celldex Therapeutics

Quite a few institutional buyers and hedge funds have not too long ago made modifications to their positions within the inventory. Virtu Monetary LLC acquired a brand new stake in shares of Celldex Therapeutics within the first quarter price about $824,000. Artal Group S.A. purchased a brand new place in shares of Celldex Therapeutics within the first quarter price about $10,618,000. California State Lecturers Retirement System elevated its stake in shares of Celldex Therapeutics by 13.5% within the first quarter. California State Lecturers Retirement System now owns 58,403 shares of the biopharmaceutical firm’s inventory price $2,451,000 after buying a further 6,929 shares in the course of the interval. Bayesian Capital Administration LP purchased a brand new place in shares of Celldex Therapeutics within the first quarter price about $470,000. Lastly, Public Workers Retirement Affiliation of Colorado purchased a brand new place in shares of Celldex Therapeutics within the first quarter price about $327,000.

About Celldex Therapeutics

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical firm, engages in growing therapeutic monoclonal and bispecific antibodies for the remedy of varied ailments. Its drug candidates embody antibody-based therapeutics to deal with sufferers with inflammatory, allergic, autoimmune, and different devastating ailments.

Beneficial Tales

Obtain Information & Rankings for Celldex Therapeutics Each day – Enter your e-mail tackle under to obtain a concise every day abstract of the newest information and analysts’ rankings for Celldex Therapeutics and associated firms with MarketBeat.com’s FREE every day e-mail e-newsletter.